MFG
CYTK icon

Merit Financial Group’s Cytokinetics CYTK Stock Holding History

Merit Financial Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$264K Sell
3,098
-122
-4% -$8.76K ﹤0.01% 1899
2026
Q1 		$212K Buy
+3,220
New +$205K ﹤0.01% 1890

Other funds holding CYTK

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Merit Financial Group's CYTK Position: Q2 2026 in Review

Merit Financial Group reduced its Cytokinetics (CYTK) stake by 3.8% in Q2 2026, selling an estimated $8.76K and leaving 3,098 shares worth $264K. The position accounts for ﹤0.01% of the portfolio, ranked #1899.

Merit Financial Group first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Merit Financial Group held 3,098 shares of Cytokinetics worth $264K as of Q2 2026.
  • Merit Financial Group sold 122 Cytokinetics shares in Q2 2026, an estimated $8.76K.
  • Cytokinetics made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #1899 holding.
  • Merit Financial Group first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.